文献速递乳腺癌支持与姑息治疗

曲妥珠单抗辅助治疗二十周年:突破性时刻的回顾

20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment.
PubMed 文献 · Ann Oncol · 2025-12-11

该综述回顾了曲妥珠单抗辅助治疗HER2阳性早期乳腺癌二十年的历程,指出关键辅助试验长期随访持续显示不同风险组和化疗骨架下生存获益显著且持久,心脏毒性总体少见且治疗结束后与普通人群相当,生物类似药和皮下制剂巩固了其临床地位,但尚无HER2以外的预测生物标志物或有效心脏保护策略。

要点

  • 曲妥珠单抗辅助治疗HER2阳性早期乳腺癌二十年仍为基石,长期随访显示生存获益显著且持久。
  • 曲妥珠单抗诱导的心脏毒性总体少见,尤其未接受蒽环类者,治疗结束后发生率与普通人群相当。
  • 除HER2过表达/扩增外,尚无经验证的预测生物标志物指导曲妥珠单抗使用。

核心结论

  • 曲妥珠单抗仍是HER2阳性早期乳腺癌治疗基石,尤其适用于较低风险患者。
  • 尽管新型抗HER2药物涌现,曲妥珠单抗可能继续作为关键治疗骨架。

研究设计与样本

  • 本文为综述,回顾曲妥珠单抗辅助治疗二十年相关关键试验长期随访及真实世界数据。

主要发现

  • 关键辅助试验长期随访持续显示不同风险组和化疗骨架下生存结局显著且持久改善。
  • 曲妥珠单抗诱导的心脏毒性总体少见,尤其无蒽环类暴露者,治疗结束后发生率与普通人群相当。
  • 真实世界数据进一步支持曲妥珠单抗长期疗效和安全性。
  • 皮下制剂和生物类似药的可及性巩固了曲妥珠单抗的临床相关性。

关键数值与推荐

  • 除HER2过表达或扩增外,尚无预测生物标志物经验证指导曲妥珠单抗使用。
  • 基质肿瘤浸润淋巴细胞、循环肿瘤DNA和HER2DX基因组检测等候选标志物尚未在临床实践中验证。
  • 临床因素和影像工具可能有助于早期识别心脏毒性高风险患者,但尚无心脏保护策略显示稳健且确证的获益。

临床怎么用

  • 曲妥珠单抗应继续作为HER2阳性早期乳腺癌,尤其是较低风险患者的治疗骨架。
  • 可利用皮下制剂和生物类似药提高治疗便利性和可及性。
  • 对无蒽环类暴露患者,曲妥珠单抗心脏毒性风险总体较低,治疗结束后可参考普通人群发生率。

局限性

  • 尚无经验证的HER2以外预测生物标志物指导曲妥珠单抗个体化使用。
  • 尚无心脏保护策略被证实具有稳健且确证的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Twenty years after its initial approval, trastuzumab remains a cornerstone in the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC). Long-term follow-up from pivotal adjuvant trials has consistently demonstrated significant and durable improvements in survival outcomes across various risk groups and chemotherapy backbones. In parallel, trastuzumab-induced cardiotoxicity (TIC) remains overall infrequent, particularly in patients without prior exposure to anthracycline and appears comparable to the incidence observed in the general population after treatment completion. While real-world data further support the long-term efficacy and safety of trastuzumab, advancements such as more convenient subcutaneous formulations and the widespread availability of more accessible cost-effective biosimilars solidify its ongoing relevance in clinical practice. Conversely, despite two decades of clinical and translational research, no predictive biomarker beyond HER2 overexpression or amplification has yet been validated to guide trastuzumab use. Emerging candidates, including stromal tumor-infiltrating lymphocytes, circulating tumor DNA, and the HER2DX genomic assay, are not yet validated for use in clinical practice, although prospective studies are ongoing. Similarly, while clinical factors and imaging tools may help identify early on patients at higher risk of experiencing TIC, no cardioprotective strategy has yet demonstrated robust and conclusive benefit. Despite the emergence of newer anti-HER2 agents and evolving treatment paradigms, trastuzumab will probably continue to serve as a key therapeutic backbone, especially for patients with lower-risk HER2-positive eBC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Gentile G, Gerosa R, de Azambuja E, et al. 20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment. Ann Oncol. 2025. PMID: 41386295. doi:10.1016/j.annonc.2025.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。